These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 7579404)

  • 41. Role of blast cell immunophenotyping for the diagnosis and prognosis of acute myeloid leukemia.
    Dubosc-Marchenay N; Lacombe F; Dumain P; Marit G; Montastruc M; Belloc F; Reiffers J
    Hematol Oncol; 1992; 10(5):235-49. PubMed ID: 1493908
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Effect of cranial irradiation on rate of recurrence in children with acute myeloid leukemia. Initial results of the AML-BFM-87 study. The AML-BFM Study Group].
    Creutzig U; Ritter J; Heyen P; Berthold F; Henze G; Kabisch H; Lampert F; Niethammer D; Riehm H; Schellong G
    Klin Padiatr; 1992; 204(4):236-45. PubMed ID: 1518259
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
    Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
    Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3.
    Scott AA; Head DR; Kopecky KJ; Appelbaum FR; Theil KS; Grever MR; Chen IM; Whittaker MH; Griffith BB; Licht JD
    Blood; 1994 Jul; 84(1):244-55. PubMed ID: 7517211
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunophenotypic, cytogenetic and clinical features of 192 AML patients in China.
    Tong H; Lu C; Zhang J; Liu Z; Ma Y
    Clin Exp Med; 2009 Jun; 9(2):149-55. PubMed ID: 19205620
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Correlation of immunophenotype to cytogenetics and clinical features of adult acute myeloid leukemia].
    Wang XB; Zheng JE; Gu JX; Yao JX; Yang J; Liu J; Li XQ; He YL; Yu JM; Wei J; Liu ZP; Huang SA
    Ai Zheng; 2005 Jun; 24(6):667-71. PubMed ID: 15946475
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunophenotyping is an independent factor for risk stratification in AML.
    Repp R; Schaekel U; Helm G; Thiede C; Soucek S; Pascheberg U; Wandt H; Aulitzky W; Bodenstein H; Sonnen R; Link H; Ehninger G; Gramatzki M;
    Cytometry B Clin Cytom; 2003 May; 53(1):11-9. PubMed ID: 12717686
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98.
    von Neuhoff C; Reinhardt D; Sander A; Zimmermann M; Bradtke J; Betts DR; Zemanova Z; Stary J; Bourquin JP; Haas OA; Dworzak MN; Creutzig U
    J Clin Oncol; 2010 Jun; 28(16):2682-9. PubMed ID: 20439630
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acute myeloid leukaemia with an unusual phenotype: myeloperoxidase (+), CD13 (-), CD14 (-) and CD33 (-).
    Seshi B; Kashyap A; Bennett JM
    Br J Haematol; 1992 Jul; 81(3):374-7. PubMed ID: 1382546
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phenotypic quantitative features of patients with acute myeloid leukemia.
    Pereira FG; Metze K; Costa FP; Lima CS; Lorand-Metze I
    Neoplasma; 2006; 53(2):155-60. PubMed ID: 16575472
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial.
    Vitale A; Guarini A; Ariola C; Meloni G; Perbellini O; Pizzuti M; De Gregoris C; Mettivier V; Pastorini A; Pizzolo G; Vignetti M; Mandelli F; Foà R
    Haematologica; 2007 Mar; 92(3):342-8. PubMed ID: 17339183
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients.
    Colovic M; Colovic N; Radojkovic M; Stanisavljevic D; Kraguljac N; Jankovic G; Tomin D; Suvajdzic N; Vidovic A; Atkinson HD
    Ann Hematol; 2012 Sep; 91(9):1363-70. PubMed ID: 22592651
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A classification based on T cell selection-related phenotypes identifies a subgroup of childhood T-ALL with favorable outcome in the COALL studies.
    Niehues T; Kapaun P; Harms DO; Burdach S; Kramm C; Körholz D; Janka-Schaub G; Göbel U
    Leukemia; 1999 Apr; 13(4):614-7. PubMed ID: 10214870
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expression of lymphoid-associated cell surface antigens by childhood acute myeloid leukemia cells lacks prognostic significance.
    Smith FO; Lampkin BC; Versteeg C; Flowers DA; Dinndorf PA; Buckley JD; Woods WG; Hammond GD; Bernstein ID
    Blood; 1992 May; 79(9):2415-22. PubMed ID: 1571553
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
    Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
    J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome.
    Casasnovas RO; Slimane FK; Garand R; Faure GC; Campos L; Deneys V; Bernier M; Falkenrodt A; Lecalvez G; Maynadié M; Béné MC
    Leukemia; 2003 Mar; 17(3):515-27. PubMed ID: 12646939
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia.
    Chang H; Salma F; Yi QL; Patterson B; Brien B; Minden MD
    Leuk Res; 2004 Jan; 28(1):43-8. PubMed ID: 14630079
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunophenotype distinction between acute promyelocytic leukaemia and CD15- CD34- HLA-DR- acute myeloid leukaemia with nucleophosmin mutations.
    Ferrari A; Bussaglia E; Úbeda J; Facchini L; Aventin A; Sierra J; Nomdedéu JF
    Hematol Oncol; 2012 Sep; 30(3):109-14. PubMed ID: 21812014
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD14+/DR--phenotypes with shorter survival. Groupe d'Etude Immunologique des Leucémies (GEIL).
    Solary E; Casasnovas RO; Campos L; Béné MC; Faure G; Maingon P; Falkenrodt A; Lenormand B; Genetet N
    Leukemia; 1992 May; 6(5):393-9. PubMed ID: 1375696
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical value of the quantitative expression of the three epitopes of CD34 in 300 cases of acute myeloid leukemia.
    Maynadié M; Gerland L; Aho S; Girodon F; Bernier M; Brunet C; Campos L; Daliphard S; Deneys V; Falkenrodt A; Jacob MC; Kühlein E; LeCalvez G; Moskovtchenko P; Philip P; Carli PM; Faure GC; Béné MC;
    Haematologica; 2002 Aug; 87(8):795-803. PubMed ID: 12161354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.